Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: BrECADD.
- Who it may be relevant to
- Registry conditions: Hodgkin Lymphoma (Category). Basic parameters: 18 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET/CT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively. A second restaging will be performed after completion of chemotherapy. In patients with PET-positive residual disease, local irradiation followed by another restaging is recommended. ART should be continued during chemotherapy.
Interventions
- Drug BrECADD
Brentuximab Vedotin Etoposide Cyclophosphamide Doxorubicin Dacarbacine Dexamethasone
Primary outcome measures
- Progression Free Survival [Time frame: PFS at 1 year]
Eligibility criteria
Inclusion criteria
- Histologically confirmed first diagnosis of cHL
- Advanced-stage disease: stage IIB with large mediastinal mass and/or extranodal lesions or stage III or IV
- No previous treatment for HL with the exception of steroid prephase
- Confirmed HIV infection with CD4 counts ≥ 150/μL at registration or > 250/μL at any time within 8 months prior to HL diagnosis
- Continuation of antiretroviral treatment (ART) / Initiation of ART in patients who are ART-naive
- Age: 18-60 years
Exclusion criteria
- Previous malignancy during last 5 years or active malignancy, prior chemotherapy or radiotherapy which precludes protocol treatment
- Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
- Multi-drug resistant HIV infection or concurrent AIDS-defining conditions
- Pregnancy or breastfeeding
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06919679 · Uni-Koeln-5576 · 2025-521749-26-00